All Stories

  1. Antiplatelet Therapy Strategies in Patients with High Bleeding Risk Treated with Complex Percutaneous Coronary Intervention: A Descriptive Study
  2. Assessing pharmacokinetics and pharmacodynamics of daily enteric-coated aspirin in patients with type 2 diabetes: the pilot APPEASED study
  3. Genetic regulation of platelet-derived BDNF by rs11030119: discrepancy between circulating levels and hemostatic function
  4. The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk
  5. Consensus on Aggregometry for platelet function testing in thrombocytopenic patients: Communication from the SSC of the ISTH
  6. Biomarkers of in vivo platelet activation in coronary artery disease: a systematic review and meta-analysis: communication from the SSC of the ISTH
  7. International opinion survey on nomenclature for platelet-type von Willebrand disease: communication from the SSC of the ISTH
  8. Early vs Delayed Bypass Surgery in Patients With Acute Coronary Syndrome Receiving Ticagrelor
  9. Can the Present Canadian Health Care System Provide Evidence-Based Pharmaceutical Care? Consideration of Two Important Cardiovascular Clinical Contexts
  10. Factor XIII-A Transglutaminase Contributes to Neutrophil Extracellular Trap (NET)-mediated Fibrin(ogen) Network Formation and Crosslinking
  11. Prospective, international, multisite comparison of platelet isolation techniques for genome-wide transcriptomics: communication from the SSC of the ISTH
  12. Standardization of definition and management for bleeding disorder of unknown cause: communication from the SSC of the ISTH
  13. Effect of Heat Exposure on Inflammation and Platelet Activity in Adults with Heart Disease
  14. The intriguing role of platelets as custodians of brain-derived neurotrophic factor
  15. Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology 2023 Focused Update of the Guidelines for the Use of Antiplatelet Therapy
  16. Association of laboratory test results with the bleeding history in patients with inherited platelet function disorders (the Bleeding Assesment Tool - LABoratory tests substudy): communication from the Platelet Physiology ISTH-SSC
  17. Megakaryocytes possess a STING pathway that is transferred to platelets to potentiate activation
  18. Alpha-2-macroglobulin prevents platelet aggregation induced by brain-derived neurotrophic factor
  19. Multicenter evaluation of light transmission platelet aggregation reagents: communication from the ISTH SSC Subcommittee on Platelet Physiology
  20. Consensus report on markers to distinguish procoagulant platelets from apoptotic platelets: communication from the Scientific and Standardization Committee of the ISTH
  21. Soluble p75 neurotrophic receptor as a reliable biomarker in neurodegenerative diseases: what is the evidence?
  22. Consensus report on flow cytometry for platelet function testing in thrombocytopenic patients: communication from the SSC of the ISTH
  23. Illustrated State-of-the-Art Capsules of the ISTH 2023 Congress
  24. Assessment of Platelet Function by High-Throughput Screening Light Transmission Aggregometry: Optimul Assay
  25. Plasminogen Activator Inhibitor-1–Positive Platelet-Derived Extracellular Vesicles Predicts MACE and the Proinflammatory SMC Phenotype
  26. Expert opinion on the use of platelet secretion assay for the diagnosis of inherited platelet function disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology
  27. Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines
  28. Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study – a cross-sectional study
  29. Aspirin for Primary Cardiovascular Prevention in Patients with Diabetes: Uncertainties and Opportunities
  30. Clinical Correlates Identify ProBDNF and Thrombo-Inflammatory Markers as Key Predictors of Circulating p75NTR Extracellular Domain Levels in Older Adults
  31. Rare missense variants in Tropomyosin‐4 (TPM4) are associated with platelet dysfunction, cytoskeletal defects, and excessive bleeding
  32. Editorial: Established and Novel Roles of Platelets in Health and Disease
  33. Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches
  34. A randomized double-blind feasibility study comparing cetirizine and diphenhydramine in the prevention of paclitaxel-associated infusion-related reactions: the PREMED-F1 study
  35. Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases
  36. Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology
  37. Differences in platelet‐rich plasma composition influence bone healing
  38. The brain-derived neurotrophic factor prompts platelet aggregation and secretion
  39. Brain-Derived Neurotrophic Factor Mitigates the Association Between Platelet Dysfunction and Cognitive Impairment
  40. Effect of Paper Versus Digital Reading in Health Professional Education: A Systematic Review and Meta-Analysis
  41. The effect of aging on the bone healing properties of blood plasma
  42. Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel
  43. A randomized double-blind pilot study comparing cetirizine with diphenhydramine in the prevention of paclitaxel-associated infusion-related reactions.
  44. The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology
  45. Dual antiplatelet therapy (PEGASUS) vs. dual pathway (COMPASS): a head-to-head in vitro comparison
  46. Platelet Function in Viral Immunity and SARS-CoV-2 Infection
  47. Platelet Quiescence in Patients With Acute Coronary Syndrome Undergoing Coronary Artery Bypass Graft Surgery
  48. Tissue-Specificity of Antibodies Raised Against TrkB and p75NTR Receptors; Implications for Platelets as Models of Neurodegenerative Diseases
  49. Severity of Megakaryocyte‐Driven Osteosclerosis in Mpig6b ‐Deficient Mice Is Sex‐Linked
  50. Acetylcholinesterase inhibitors and risk of bleeding and acute ischemic events in non‐hypertensive Alzheimer's patients
  51. Implications of the Antiplatelet Therapy Gap Left with Discontinuation of Prasugrel in Canada
  52. Platelets Selectively Regulate the Release of BDNF, But Not That of Its Precursor Protein, proBDNF
  53. Postoperative Administration of the Acetylcholinesterase Inhibitor, Donepezil, Interferes with Bone Healing and Implant Osseointegration in a Rat Model
  54. Advances in Platelet Function Testing—Light Transmission Aggregometry and Beyond
  55. Platelet count and disease – editorial policy
  56. Effects of reading media on reading comprehension in health professional education
  57. Differential correlation of serum BDNF and microRNA content in rats with rapid or late onset of heavy alcohol use
  58. Head-to-Head Comparison of Consensus-Recommended Platelet Function Tests to Assess P2Y12 Inhibition—Insights for Multi-Center Trials
  59. Differential Correlation of Serum BDNF and microRNA Content in Rats with Rapid or Late Onset of Heavy Alcohol Use
  60. Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC
  61. A Critical Comparison of Canadian and International Guidelines Recommendations for Antiplatelet Therapy in Coronary Artery Disease
  62. Platelet Function in Aging
  63. Study of the bioaccumulation of tinzaparin in renally impaired patients when given at prophylactic doses - The STRIP study
  64. Clinical Tests of Platelet Function
  65. 750
  66. Increased platelet reactivity and platelet–leukocyte aggregation after elective coronary bypass surgery
  67. An interview with Professor Gus Born
  68. Clinical importance of thrombocytopenia in patients with acute coronary syndromes: a systematic review and meta-analysis
  69. 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy
  70. Platelets at the heart of therapy
  71. Ischemic and bleeding outcomes after coronary artery bypass grafting among patients initially treated with a P2Y12 receptor antagonist for acute coronary syndromes: Insights on timing of discontinuation of ticagrelor and clopidogrel prior to surgery
  72. Personalizing antiplatelet therapies: What have we learned from recent trials?
  73. Tailored antiplatelet therapy in high-risk ACS patients treated with PCI stenting: lessons from the ANTARCTIC trial
  74. Mice Lacking the Inhibitory Collagen Receptor LAIR-1 Exhibit a Mild Thrombocytosis and Hyperactive PlateletsHighlights
  75. PREVALENCE AND CLINICAL IMPACT OF THROMBOCYTOPENIA IN PATIENTS WITH ACUTE CORONARY SYNDROMES: A SYSTEMATIC REVIEW AND META-ANALYSIS
  76. Platelet function one and three months after coronary bypass surgery in relation to once or twice daily dosing of acetylsalicylic acid
  77. Platelet Function Tests
  78. Tests of Platelet Function
  79. ISCHEMIC AND BLEEDING OUTCOMES AFTER CORONARY ARTERY BYPASS GRAFTING AMONG PATIENTS INITIALLY TREATED WITH A P2Y12 RECEPTOR ANTAGONIST FOR ACUTE CORONARY SYNDROMES - INSIGHTS ON THE USE OF TICAGRELOR VERSUS CLOPIDOGREL PRIOR TO SURGERY
  80. ISCHEMIC AND BLEEDING OUTCOMES AFTER CORONARY ARTERY BYPASS GRAFTING AMONG PATIENTS INITIALLY TREATED WITH A P2Y12 RECEPTOR ANTAGONIST FOR ACUTE CORONARY SYNDROMES - INSIGHTS ON TIMING OF DISCONTINUATION OF TICAGRELOR AND CLOPIDOGREL PRIOR TO SURGERY
  81. The Effects of Different Aspirin Dosing Frequencies and the Timing of Aspirin Intake in Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review
  82. Platelet function testing as a biomarker for efficacy of antiplatelet drugs
  83. Whole exome sequencing identifies genetic variants in inherited thrombocytopenia with secondary qualitative function defects
  84. Platelet function tests
  85. Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation
  86. Is platelet transfusion the solution to reverse platelet inhibition in patients on triple antiplatelet therapy?
  87. SLFN14 mutations underlie thrombocytopenia with excessive bleeding and platelet secretion defects
  88. The role of platelets in the recruitment of leukocytes during vascular disease
  89. Investigating the effectiveness of different aspirin dosing regimens and the timing of aspirin intake in primary and secondary prevention of cardiovascular disease: protocol for a systematic review
  90. Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis
  91. The prognostic utility of tests of platelet function for the detection of ‘aspirin resistance’ in patients with established cardiovascular or cerebrovascular disease: a systematic review and economic evaluation
  92. Use of next‐generation sequencing and candidate gene analysis to identify underlying defects in patients with inherited platelet function disorders
  93. Diversity and impact of rare variants in genes encoding the platelet G protein-coupled receptors
  94. Methodological issues and recommendations for systematic reviews of prognostic studies: an example from cardiovascular disease
  95. Evidence of platelet sensitization to ADP following discontinuation of clopidogrel therapy in patients with stable coronary artery disease
  96. A novel mutation in the P2Y12 receptor and a function‐reducing polymorphism in protease‐activated receptor 1 in a patient with chronic bleeding
  97. Evaluation of a whole blood remote platelet function test for the diagnosis of mild bleeding disorders
  98. Characterization of multiple platelet activation pathways in patients with bleeding as a high-throughput screening option: use of 96-well Optimul assay
  99. A novel thromboxane A2 receptor N42S variant results in reduced surface expression and platelet dysfunction
  100. Enrichment of FLI1 and RUNX1 mutations in families with excessive bleeding and platelet dense granule secretion defects
  101. Utility of the ISTH bleeding assessment tool in predicting platelet defects in participants with suspected inherited platelet function disorders
  102. Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists
  103. Corrigendum
  104. Genotyping and phenotyping of platelet function disorders
  105. Testing Platelet Function
  106. Simultaneous measurement of ATP release and LTA does not potentiate platelet aggregation to epinephrine
  107. Microsatellite markers as a rapid approach for autozygosity mapping in Hermansky-Pudlak syndrome: Identification of the second HPS7 mutation in a patient presenting late in life
  108. OC-13 Investigation of underlying platelet function defects in patients with unexplained menorrhagia
  109. Protocol for a systematic review of the diagnostic and prognostic utility of tests currently available for the detection of aspirin resistance in patients with established cardiovascular or cerebrovascular disease
  110. Clinical Tests of Platelet Function
  111. G6f-Like Is an ITAM-Containing Collagen Receptor in Thrombocytes
  112. Platelet Turnover in Atherothrombotic Disease
  113. Evaluation of participants with suspected heritable platelet function disorders including recommendation and validation of a streamlined agonist panel
  114. Advances in monitoring of aspirin therapy
  115. Aspirin twice a day keeps new COX-1 at bay
  116. 50th anniversary of the discovery of ibuprofen: an interview with Dr Stewart Adams
  117. Genetic determinants of response to aspirin: Appraisal of 4 candidate genes
  118. Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease
  119. Beware of being caught on the rebound
  120. Why an aspirin a day no longer keeps the doctor away …
  121. Platelet count, not oxidative stress, may contribute to inadequate platelet inhibition by aspirin
  122. Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel
  123. Prevalence of Unresponsiveness to Aspirin and/or Clopidogrel in Patients With Stable Coronary Heart Disease
  124. Evaluation of the platelet count drop method for assessment of platelet function in comparison with “gold standard” light transmission aggregometry
  125. Week-Long High-Maintenance Dose Clopidogrel Regimen Achieves Better Platelet Aggregation Inhibition than a Standard Loading Dose before Percutaneous Coronary Intervention: Results of a Double-Blind, Randomized Clinical Trial
  126. Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: A look at the clinical and pharmacological evidence
  127. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B2
  128. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients
  129. Assessment of VerifyNow P2Y12 Assay Accuracy in Evaluating Clopidogrel-Induced Platelet Inhibition
  130. Comparison of different methods of measurement of aspirin resistance: using the appropriate statistic: reply
  131. Normal Response to Aspirin in Healthy Individuals: Cross-Comparison of Light Transmission Aggregometry, VerifyNow™ System, Platelet Count Drop, Thrombelastography (TEG®) and Urinary 11-dehydrothromboxane B2.
  132. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease
  133. Aspirin resistance: Truth or dare